|
EQS-Ad-hoc: FamiCord AG / Key word(s): Annual Results/Forecast
FamiCord AG significantly exceeds annual earnings guidance for 2024 on the basis of preliminary figures
10-Apr-2025 / 17:35 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
FamiCord AG significantly exceeds annual earnings guidance for 2024 on the basis of preliminary figures
Leipzig, 10 April 2025 – FamiCord AG has significantly exceeded its earnings guidance for the 2024 financial year. This is the conclusion reached by the Management Board on the basis of the preliminary business figures available today. Based on these preliminary figures, revenue amounted to EUR 82.2 million and earnings before interest, taxes, depreciation and amortization (EBITDA) to EUR 8.8 million. As part of the guidance for the 2024 financial year, the Management Board expected revenue of between EUR 81 million and EUR 88 million and EBITDA of between EUR 6.5 million and EUR 8.0 million. The deviation in earnings from the upper end of the guidance range is therefore around 10 percent.
Notifying Person: Jakub Baran (CEO)
--- End of inside information according to Art. 17 MAR ---
End of Inside Information
Information and Explanation of the Issuer to this announcement:
The Company will publish the full 2024 annual report as planned on 30 April 2025.
Contact:
FamiCord AG
Investor Relations
Phone: +49 (0341) 487920
Email: ir@famicord.com
Company profile
FamiCord (formerly Vita 34) was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since offered the collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissues as a full-service provider for cryopreservation. The donor's own cells are a valuable starting material for medical cell therapy and are kept alive in the vapor of liquid nitrogen. Customers from about 50 countries have already provided for the health of their families with about one million units of stored biological material at FamiCord. Furthermore, the Company is active in the areas of Cell & Gene therapies and CDMO.
10-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
|